Jaguar Health, Inc.

JAGX

US47010C8055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
4.11 ^USD	-1.44%		+1.48%	-54.76%

08/07	Jaguar Health Unit Secures New European, Australian Patents; Shares Rise	MT
30/05	Top Premarket Gainers	MT

Jaguar Health, Inc. announced that it has received $0.8011 million in funding

January 11, 2018

On January 11, 2018, Jaguar Health, Inc. (NasdaqCM:JAGX) closed the transaction. The company received $801,100 in funding from six investors.

Latest news about Jaguar Health, Inc.

Jaguar Health Unit Secures New European, Australian Patents; Shares Rise	08/07	MT
Top Premarket Gainers	30/05	MT
Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences	29/05	MT
Jaguar Health, Inc. Executes Out- License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia	29/05	CI
Jaguar Health, Inc. Announces Results of Third-Party, Investigator-Initiated Study of Crofelemer	28/05	CI
Jaguar Health Plans 1-for-60 Reverse Split Next Week	18/05	MT
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M	14/05	MT
Transcript : Jaguar Health, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	06/05	MT
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	06/05	CI
Venture Life renews revolving credit facility with Santander and HSBC	19/04	AN
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	18/04	CI
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	10/04	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	10/04	MT
Top Premarket Gainers	10/04	MT
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International	04/04	CI
Transcript : Jaguar Health, Inc., Q4 2023 Earnings Call, Apr 01, 2024	01/04
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	15/02	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	15/02	CI
Top Premarket Gainers	26/01	MT
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	11/12	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	04/12	CI
Jaguar Health, Inc. announced that it has received $0.06 million in funding	30/11	CI

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.11 USD

Average target price

36 USD

Spread / Average Target

+775.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
JAGUAR HEALTH, INC.	-54.76%	21.71M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.79%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.41%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs